Growth Plus Reports Logo.jpg
Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market is Expected to Reach US$ 82.3 billion by 2030, Growth Plus Reports
January 31, 2023 05:20 ET | Growth Plus Reports
Newark, New Castle, USA, Jan. 31, 2023 (GLOBE NEWSWIRE) -- According to the latest report published by Growth Plus Reports, global epilepsy with myoclonic-atonic seizures therapeutics market is...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals Completes the Acquisition of U.S. Rights to FYCOMPA® (Perampanel) CIII
January 25, 2023 08:03 ET | Catalyst Pharmaceuticals, Inc.
Strengthens its Commercial Portfolio with the First and Only AMPA Receptor Antagonist Marketed Product for Epilepsy Bolsters Presence in Neuroscience Expected to be Accretive in 2023 ...
Global Neuromonitoring Devices Market Anticipated to Generate a Revenue of $10,276.0 Million and Rise at a CAGR of 7.24% during the Analysis Period from 2022 to 2030 [210-Pages] | Details by Research Dive
January 19, 2023 09:02 ET | Research Dive
New York, USA, Jan. 19, 2023 (GLOBE NEWSWIRE) -- According to the report published by Research Dive, the global neuromonitoring devices market is expected to generate $10,276.0 million in revenue...
Catalyst Pharmaceutical logo
Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd
December 19, 2022 16:10 ET | Catalyst Pharmaceuticals, Inc.
Acquisition Expands The Company’s Commercial Portfolio With An Established U.S. Marketed Product Company Remains Dedicated To Growth Within Neurology Through Continued Active Business Development...
Praxis Precision Medicines and UCB Announce Epilepsy Research Collaboration
December 13, 2022 16:01 ET | Praxis Precision Medicines, Inc.
BOSTON, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company, and UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical...
SciSparc Announces Positive Study Results with SCI-210, a Cannabidiol-Based Treatment for Epilepsy
December 07, 2022 08:40 ET | SciSparc Ltd
The non- clinical study was conducted at The Chaim Sheba Medical Center in Israel Tel-Aviv, Dec. 07, 2022 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC), a specialty, clinical-stage...
Neurona Therapeutics Presents Clinical Data for NRTX-1001 Regenerative Cell Therapy for Drug-Resistant Focal Epilepsy at American Epilepsy Society Annual Meeting
December 05, 2022 08:00 ET | Neurona Therapeutics
NRTX-1001 administration was well-tolerated, with notable seizure reduction reported in early data from the first two patients in Phase I/II clinical trial Additional preclinical data highlight...
Zeto-encevis PR
Zeto Implements encevis' Seizure Detection and Trending Algorithms
December 01, 2022 08:00 ET | Zeto, Inc.
SANTA CLARA, Calif., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Zeto, Inc., an innovative EEG brain monitoring company, announced today the integration of FDA cleared seizure detection and trending...
uniQure Highlights Therapeutic Potential of AMT-260 in Refractory Temporal Lobe Epilepsy (rTLE) at Virtual Research & Development Event
November 29, 2022 11:00 ET | uniQure Inc.
~ IND Submission and Clinical Development Expected to Begin in 2023 ~ ~ Advancements in Manufacturing and Technology Platform Also Highlighted ~ LEXINGTON, Mass. and AMSTERDAM, the Netherlands,...
Praxis Precision Medicines to Present at the American Epilepsy Society 2022 Annual Meeting
November 28, 2022 16:05 ET | Praxis Precision Medicines, Inc.
BOSTON, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies...